Brasada Capital Management LP Buys 15,291 Shares of Stryker Co. (NYSE:SYK)

Brasada Capital Management LP increased its stake in Stryker Co. (NYSE:SYK - Free Report) by 805.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 17,190 shares of the medical technology company's stock after purchasing an additional 15,291 shares during the period. Stryker makes up 1.1% of Brasada Capital Management LP's holdings, making the stock its 28th biggest holding. Brasada Capital Management LP's holdings in Stryker were worth $6,205,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. MGO One Seven LLC raised its position in Stryker by 38.4% during the fourth quarter. MGO One Seven LLC now owns 3,397 shares of the medical technology company's stock valued at $1,223,000 after purchasing an additional 942 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Stryker by 0.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 11,109,722 shares of the medical technology company's stock worth $4,000,056,000 after buying an additional 54,693 shares during the last quarter. Dark Forest Capital Management LP boosted its stake in Stryker by 3.3% in the fourth quarter. Dark Forest Capital Management LP now owns 2,483 shares of the medical technology company's stock valued at $894,000 after buying an additional 79 shares in the last quarter. Alta Advisers Ltd grew its position in Stryker by 25.7% in the fourth quarter. Alta Advisers Ltd now owns 1,131 shares of the medical technology company's stock valued at $407,000 after acquiring an additional 231 shares during the last quarter. Finally, SIH Partners LLLP bought a new position in shares of Stryker in the fourth quarter worth about $1,080,000. Institutional investors own 77.09% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on SYK. BTIG Research set a $403.00 price objective on shares of Stryker and gave the company a "buy" rating in a research note on Monday, April 14th. JMP Securities reiterated a "market perform" rating on shares of Stryker in a research report on Tuesday, February 18th. Citigroup reaffirmed a "buy" rating and set a $450.00 price target on shares of Stryker in a research note on Wednesday, February 26th. Stifel Nicolaus increased their price objective on Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. Finally, Royal Bank of Canada increased their price target on Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a research note on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Stryker presently has an average rating of "Moderate Buy" and a consensus price target of $423.53.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 201,392 shares of the business's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.20% of the stock is owned by corporate insiders.

Stryker Trading Up 2.7 %

Shares of Stryker stock opened at $348.62 on Wednesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The stock has a 50 day moving average price of $369.25 and a two-hundred day moving average price of $373.06. The stock has a market capitalization of $133.06 billion, a PE ratio of 44.93, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the business earned $3.46 EPS. As a group, equities analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.96%. The ex-dividend date is Monday, March 31st. Stryker's dividend payout ratio (DPR) is presently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.